Skip to content

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2011-002026-52-FR
Enrollment
490
Registered
2011-06-27
Start date
2011-10-11
Completion date
Unknown
Last updated
2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 14.0 Level: LLT Classification code 10051971 Term: Pancreatic adenocarcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Interventions

Trade Name: GEMZAR Pharmaceutical Form: Solution for infusion INN or Proposed INN: GEMCITABINE CAS Number: 95058-81-4 Concentration unit: mg milligram(s) Concentration type: range Concentration number

Sponsors

Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):

Countries

France

Contacts

Public ContactBéata JUZYNA - Chef de Projet

FNCLCC

b-juzyna@unicancer.fr01 44 23 55 67

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 11, 2026